

25 SEPTEMBER 2023

\$1.95 MILLION ORDER FOR PRODUCTS FOR SHANGHAI NO. 1 PHARMACEUTICALS

- RLG receives orders for \$1.95m of products for Shanghai No.1 Pharmaceuticals Company pharmacy stores
- Shanghai stock exchange listed Shanghai No.1 Pharmaceuticals Company (600833.SS) operates pharmacies in China and provides an important sales and distribution channel in China for RLG
- A total of \$2.9m in product orders have been received within the first month of the partnership which was announced 30 August 2023
- Joint business development activities identifying high demand products and marketing of RLG's portfolio of health & well-being and food & beverage products under way and delivering results
- Additional product orders expected over the coming Quarter

e-Commerce company RooLife Group Ltd (**ASX:RLG**) ("**RLG**" or "**Company**") is delighted to advise receipt of the second major order for products to be sold in China online and in physical stores of Shanghai No.1 Pharmaceuticals Co., Ltd ("**Shanghai No.1 Pharmacy**").

Through its RLG Marketplace Pty Ltd subsidiary, **\$1,950,000** of additional product orders have been received in September, which follows the maiden order valued at **\$950,000** received upon the signing of the agreement announced 30 August 2023.

These orders for dairy and food products are to supply and service identified demand for products to be sold in China through Shanghai No. 1 Pharmacy's stores in cities including Qingdao, Ningbo and Tianjin, as RLG continues to broaden its channels and customer reach through China.

Total value of orders received for Shanghai No. 1 Pharmacy in the first month of co-operation is now approximately **\$2,900,000** with product sourcing underway and revenue expected to be recognised in the coming quarter. Ongoing business development with partner AULife International is focussed on securing additional product orders for RLG's portfolio of products over the coming Quarter with all transactions managed by individual purchase orders for products required, with no minimum order requirements.



Shanghai No.1 Pharmaceuticals Company (600833.SS) is a Shanghai stock exchange listed company engaged in pharmaceutical wholesaling and retailing and operates an extensive network of regular chain drug stores in China and online market place. It is part of the large state-owned Bailian Group (www.bailiangroup.cn/html/english) and so is a strong and natural fit with RLG's business model for marketing and distributing international health, well-being, food and beverage products in China.

RooLife Group CEO, Bryan Carr said: "Receiving these substantial orders within the first month of our arrangement to supply products to Shanghai No.1 Pharmacy confirms the value of this partnership. We have now received sales orders just short of \$3 million within the first month following the announcement of this distribution agreement, which is a fantastic start with a new sales channel.

The co-operation and business development underway and with partner AULife to identify products in demand that we can jointly go to market with is very exciting. Expanding and delivering these new distribution channels provides additional opportunities for growth for our partner health, food and beverage clients in China.

We look forward to providing further updates as we secure additional sales channels and supply contracts for our health, wellbeing and food and beverage product range."



ENDS

Issued by: RooLife Group Ltd

Authorised by: The Board of RooLife Group Ltd

For further information, please visit the RooLife website at www.roolifegroup.com.au or contact:

Bryan Carr

Managing Director Ph: +61 8 6444 1702

Email: ir@roolifegroup.com.au